|
|
Volumn 3, Issue 2, 2006, Pages 62-63
|
|
The investigational new drug application - Who benefits?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEW DRUG;
THALIDOMIDE;
CANCER MORTALITY;
CLINICAL RESEARCH;
DRUG APPROVAL;
DRUG LEGISLATION;
DRUG RESEARCH;
DRUG SCREENING;
ECONOMIC EVALUATION;
FINANCIAL MANAGEMENT;
GENETICS;
GOVERNMENT;
HUMAN;
INSTITUTIONAL REVIEW;
PATIENT SELECTION;
PRIORITY JOURNAL;
PROCESS MONITORING;
REVIEW;
RISK BENEFIT ANALYSIS;
TERATOGENICITY;
ACADEMIC MEDICAL CENTERS;
ANTINEOPLASTIC AGENTS;
ETHICS COMMITTEES, RESEARCH;
GOVERNMENT REGULATION;
HUMAN EXPERIMENTATION;
HUMANS;
INVESTIGATIONAL NEW DRUG APPLICATION;
NEOPLASMS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 32844465088
PISSN: 17434254
EISSN: None
Source Type: Journal
DOI: 10.1038/ncponc0429 Document Type: Review |
|
Times cited : (6)
|
|
References (7)
|
